Article by Anisha Dhiman, Growth Op
Ten-year-old Teagan Appleby suffers from a rare genetic condition called Idic 15, which causes seizures.
With medical cannabis, the child’s daily seizure count reportedly dropped from 300 to 10 — as low as two on a good day. But Teagan’s mother, Emma, fears COVID-19 threatens their supply.
“Things have been difficult,” U.K. resident Emma Appleby tells Kent Online. The family ran out of Celixir, which is imported from Israel, two weeks ago. There were shipping delays because of COVID-19, but a new shipment arrived just in the nick of time. “Now we are worried about the next batch arriving on time,” mother Emma says.
Affordability has been a challenge, too. Prescribed medical cannabis was legalized in the U.K. in 2018, but it can be expensive because it’s not subsidized by the National Health Service. Appleby’s prescription costs up to £1,500 each time (more than $2,500).
The family launched an online campaign to raise £5,000 (almost $9,000), but have found it more difficult to raise money in the wake of the pandemic.